#TPST

Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules Tempest Therapeutics (Nasdaq: TPST) announced a registered direct offering of 1,172,414 shares at $3.625 per share for aggregate gross proceeds of approximately $4.25 million, and a concurrent private placement of short-term unregistered warrants to purchase up to 1,172,414 shares at an exercise price of $3.50.The warrants are immediately exercisable, expire 18 months after the registration statement becomes effective, and could provide up to an additional $4.1 million if fully exercised. Closing is expected on or about November 25, 2025. Net proceeds are intended for working capital and general corporate purposes; H.C. Wainwright is placement agent.

3 months ago

#TPST Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

www.stocktitan.net/news/TPST/tempest-announ...

0 0 0 0

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027 Tempest (Nasdaq: TPST) agreed to acquire Factor Bioscience’s clinical dual‑CAR T programs in an all‑stock transaction announced Nov 19, 2025, expected to close in early 2026 subject to shareholder approval and closing conditions.The deal issues 8,268,495 shares (65% of outstanding) to a Factor affiliate, grants Tempest global rights outside China/India/Turkey/Russia to TPST-2003, and includes a Factor investment commitment expected to extend Tempest’s runway to mid 2027. TPST-2003 has a completed Phase 1 in rrMM with China BLA planned for 2027 and additional program milestones and trials slated for 2026–2028. Leadership changes and warrants to existing holders are included.

3 months ago

#TPST Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027

www.stocktitan.net/news/TPST/tempest-announ...

0 0 0 0

4 months ago

#TPST Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/TPST/tempest-report...

0 0 0 0

WONHO BRASIL

@wonhobrasil.bsky.social

4 months ago

TikTok, Reels & YT Shorts | 03.11.25

if you wanna com #LEW

🖇️ m.youtube.com/shorts/_ew7e...
🖇️ vt.tiktok.com/ZSyBKL4ns/
🖇️ instagram.com/reel/DQlqk8LAR…

#원호 #WONHO
#TEMPEST #TPST #템페스트
#SYNDROME #ifyouwanna
#ifyouwanna_challenge

1 0 0 0

WONHO Update

@wonhoupdate.bsky.social

4 months ago

if you wanna❤️‍🔥🧊with #LEW @TPSTOFFICIAL YouTube video by WONHO

[ #원호숏폼]
if you wanna❤️‍🔥🧊with #LEW
#Tempest

🔗 youtube.com/shorts/_ew7e...
🔗 vt.tiktok.com/ZSyBKL4ns/
🔗 www.instagram.com/reel/DQlqk8L...

#원호 #WONHO
#TEMPEST #TPST #템페스트
#SYNDROME #ifyouwanna
#ifyouwanna_challenge

5 1 0 0

4 months ago

TEMPEST(템페스트) - In The Dark (어둠 속에서) M/V YouTube video by TEMPEST

TEMPEST - In The Dark MV

#TEMPEST #TPST #템페스트 #kpop

1 0 0 0

4 months ago

TEMPEST - 'CHILL' Live Clip YouTube video by TEMPEST

TEMPEST - Chill live clip MV

#TEMPEST #TPST #템페스트 #As_I_am #CHILL #kpop

0 0 0 0

4 months ago

TEMPEST(템페스트) – 7th Mini Album [As I am] HIGHLIGHT MEDLEY YouTube video by TEMPEST

Medley time!

TEMPEST - As I Am highlight medley

#TEMPEST #TPST #템페스트 #As_I_am #In_The_Dark #kpop

1 1 0 0

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update Tempest Therapeutics (NASDAQ: TPST) reported Q2 2025 financial results and significant clinical developments. The company received clearance for a pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC) in China, complementing existing FDA and EMA approvals. Amezalpat secured orphan drug designation from both the EMA and FDA, along with Fast Track designation for HCC treatment.Financially, Tempest ended Q2 with $14.3 million in cash, down from $30.3 million in December 2024. The company reported a net loss of $7.9 million ($2.07 per share) and completed a $4.6 million registered direct offering in June 2025. The company is actively exploring strategic alternatives to maximize stockholder value while implementing cost-cutting measures.

7 months ago

#TPST Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/TPST/tempest-report...

0 0 0 0

7 months ago

TEMPEST - My Way | Official Video YouTube video by TEMPEST

TEMPEST - My Way MV

#TEMPEST #TPST #템페스트 #テンペスト #MyWay

3 0 0 0

Tempest's Novel Cancer Drug Gets Green Light for Crucial China Trial in World's Largest Liver Cancer Market Tempest advances amezalpat combination therapy with NMPA approval for pivotal trial in China's hepatocellular carcinoma market. See global expansion strategy.

8 months ago

#TPST Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

www.stocktitan.net/news/TPST/tempest-receiv...

0 0 0 0

Tempest Therapeutics Raises $4.6M From Single Institutional Investor: Strategic Alternative Process Funded Biotech firm secures crucial financing through registered direct offering to single institutional investor. See how proceeds will advance strategic alternatives process.

9 months ago

#TPST Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

www.stocktitan.net/news/TPST/tempest-announ...

0 0 0 0

HumanAlgoHybrid

@humanalgohybrid.bsky.social

9 months ago

Top after-hours breakouts in penny stocks for Friday, June 06, 2025 sorted by range are $TPST $12.25 (49%), $MB $9.37 (21%), $ORGO $3.39 (12%), $SRFM $2.68 (12%) #TPST #chartanalysis #tradingstrategy #daytrading

0 0 0 0

Breakthrough Liver Cancer Drug Shows 6-Month Survival Benefit, Secures Crucial EU and FDA Support New liver cancer treatment amezalpat demonstrates 6-month survival advantage in Phase 1b/2 trial. EMA grants orphan status following strong clinical data. See full results.

9 months ago

#TPST Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

www.stocktitan.net/news/TPST/tempest-receiv...

0 0 0 0

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update Tempest Therapeutics (NASDAQ: TPST) reported Q1 2025 financial results and corporate updates. The company presented new data for amezalpat at AACR, demonstrating its potential in cancer treatment by reducing immunosuppression. Key developments include: FDA granting both Orphan Drug and Fast Track designations for amezalpat in hepatocellular carcinoma (HCC) treatment, and Orphan Drug designation for TPST-1495 in familial adenomatous polyposis (FAP). Financially, Tempest ended Q1 with $21.5 million in cash, down from $30.3 million in December 2024. The company reported a net loss of $10.9 million ($3.16 per share) compared to $7.9 million in Q1 2024. R&D expenses increased to $7.6 million, primarily due to preparation for amezalpat's Phase 3 trial. The company announced plans to explore strategic alternatives and completed a workforce reduction in April 2025.

10 months ago

#TPST Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/TPST/tempest-report...

0 0 0 0

Breakthrough: New Cancer Drug Amezalpat Demonstrates Dual Anti-Cancer Mechanism in Multiple Tumors Tempest's amezalpat reveals groundbreaking dual mechanism targeting cancer immunosuppression. New AACR data validates efficacy in multiple tumor types. See full results.

10 months ago

#TPST Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

www.stocktitan.net/news/TPST/tempest-presen...

0 0 0 0

FDA Awards Rare Disease Drug Status to Tempest's Novel FAP Treatment: Phase 2 Trial Coming in 2025 Tempest secures crucial FDA designation for rare disease drug TPST-1495. NCI-funded Phase 2 trial launches 2025. See development timeline.

10 months ago

#TPST Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

www.stocktitan.net/news/TPST/tempest-receiv...

0 0 0 0

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value Tempest Therapeutics (NASDAQ: TPST) has announced plans to explore strategic alternatives to advance its clinical-stage oncology programs and maximize stockholder value. The company has retained MTS Health Partners as financial advisor for this process.Key highlights include:Their lead drug amezalpat (TPST-1120) is Phase 3-ready for first-line hepatocellular carcinoma (HCC) treatment, having received both Orphan Drug and Fast Track designationsPhase 1b/2 clinical study showed amezalpat improved median overall survival by six months when combined with atezolizumab and bevacizumabFDA has issued "Study May Proceed" letter for TPST-1495 in Phase 2 trial for familial adenomatous polyposis (FAP) treatment, with data expected in 2026The company has established an agreement with Roche for evaluating amezalpat in combination therapy

11 months ago

#TPST Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

www.stocktitan.net/news/TPST/tempest-announ...

0 0 0 0

Market Wire News

@marketwirenews.com

11 months ago

BREAKING NEWS: ( NASDAQ: #TPST ) TPST announced stock split 1-13

0 0 0 0

11 months ago

TEMPEST - 6TH MINI ALBUM [RE: Full of Youth] HIGHLIGHT MEDLEY YouTube video by TEMPEST

Medley time!

TEMPEST - Full of Youth album highlight medley

#TEMPEST #TPST #템페스트 #RE_Full_of_Youth #Unfreeze

0 0 0 0

Tempest Reports Year End 2024 Financial Results and Provides Business Update Tempest Therapeutics (NASDAQ: TPST) reported significant progress in 2024, highlighted by key developments for their cancer therapeutics. Their lead drug Amezalpat received both Orphan Drug and Fast Track designations from the FDA for Hepatocellular Carcinoma (HCC) treatment. The company secured an agreement with Roche to advance Amezalpat into a Phase 3 trial.Clinical results showed Amezalpat delivered a six-month improvement in median overall survival when combined with standard treatments for HCC. For TPST-1495, the company received FDA clearance for a Phase 2 trial in Familial Adenomatous Polyposis.Financial results showed cash position of $30.3 million at year-end, down from $39.2 million in 2023. Net loss increased to $41.8 million ($1.50 per share) compared to $29.5 million ($1.91 per share) in 2023. R&D expenses rose to $28.5 million from $17.5 million, while G&A expenses increased to $13.6 million from $11.7 million.

11 months ago

#TPST Tempest Reports Year End 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/TPST/tempest-report...

0 0 0 0

Breakthrough Cancer Drug Data Reveals New Immune Response Findings at AACR 2025 Novel cancer treatment amezalpat shows promising immune response data in latest clinical findings. Key mechanism of action insights to be revealed at AACR 2025.

11 months ago

#TPST Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

www.stocktitan.net/news/TPST/tempest-announ...

0 0 0 0

FDA Green Light: Tempest's Revolutionary FAP Drug Advances to Phase 2 with NCI Backing NCI-funded Phase 2 trial for Tempest's dual receptor inhibitor targets Familial Adenomatous Polyposis, marking company's second advanced clinical program.

1 year ago

#TPST FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

www.stocktitan.net/news/TPST/fda-study-may-...

0 0 0 0

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage

1 year ago

#TPST Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

www.stocktitan.net/news/TPST/tempest-grante...

0 0 0 0

1 year ago

[Sent at 13:43]

Hi~

I'm currently doing my best

What are you doing?

#tpst #TEMPEST #hyuk #혁 #ヒョク #템페스트 #テンペスト

0 0 0 0

1 year ago

2025.02.02 Hyuk 🫧

[Sent at 2:07]

Lulu Lala

I came back from reading on WeVerse

It's time to sleep

Goodnight..

See you tomorrow okkayyy

Hehe

I love you always~ 🤍

#tpst #TEMPEST #hyuk #혁 #ヒョク #템페스트 #テンペスト

0 0 1 0

1 year ago

[Sent at 23:07]

I wanna see you,,

I read the letters from the official fan café

Hahah

The period with nothing/gaps,

Are really sad and depressing

Eh, what's wrong

I can't enter the chat

It's a network error,

It seems.

Oh my

#tpst #TEMPEST #hyuk #혁 #ヒョク #템페스트 #テンペスト

0 0 0 0